Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | PRKACG | P22612 | 2/20 | 0.49 |
| ▸ | PRKACB | P22694 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2864651 | 0.92 | APEX1 (0.52) | TP53MAPTSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL2864643 | 0.85 | SMN1; SMN2 (0.56) | TP53MAPTSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL2862186 | 0.85 | SMN1; SMN2 (0.56) | TP53MAPTSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL13198231 | 0.82 | MAPT (0.51) | TP53MAPTSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL2858848 | 0.82 | ROCK2 (0.59) | MAPTSMN1; SMN2ROCK2ROCK1PRKACA | |
| SCHEMBL4334940 | 0.80 | MAP4K4 (0.48) | — | |
| SCHEMBL4338790 | 0.80 | RECQL (0.48) | TP53ROCK2ROCK1KDM4EUSP2 | |
| SCHEMBL2868742 | 0.80 | TTK (0.57) | MAPTSMN1; SMN2ROCK2ROCK1MMP13 | |
| SCHEMBL2856935 | 0.80 | SMN1; SMN2 (0.54) | MAPTSMN1; SMN2ROCK2ROCK1PRKACA | |
| SCHEMBL27536113 | 0.80 | MAP2K4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | TP53 1560/4885MAPT 2644/4885SMN1; SMN2 4812/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | TP53 2280/4885MAPT 2892/4885SMN1; SMN2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.